AN2 Therapeutics ANTX 深 沪
等待开盘 07-11 09:30:00 美东时间
4.50
-0.130
-2.81%
华盛通- 最 高4.68
- 今 开4.62
- 成交量 59.17万股
- 最 低 4.28
- 昨 收 4.63
- 总市值 1.62亿
- 52周最高 6.9099
- 市盈率 静 --
- 换手率 1.64%
- 52周最低 1.00
- 委 比 93.25%
- 总股本 3601.62万
- 历史最高 23.58
- 量 比 2.69
- 振 幅 8.64%
- 历史最低 0.87
- 每 手 1
- 风险率 1.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi
Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humansPhase 1 First-In-Human (FIH) study showed
06-04 19:09
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform and announces $9 price target.
05-15 04:35
AN2 Therapeutics Initiates Phase 2 Trial Of leucyl-tRNA Synthetase (LeuRS) Mycobacterium Abscessus, With Topline Data Planned For Late 2027
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2
03-31 19:07
AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 16 percent decrease over losses of $(0.25) per share from
03-18 04:07
AN2 Therapeutics Stock Cools Off After 90% Rally
AN2 Therapeutics stock dips in premarket after a 90% surge tied to a $40 million equity raise.
03-11 21:52
美股牛股 | 医药股齐升！Xenon制药飙升近50%，癫痫新药临床试验获重大突破；HIMS大涨40%
医药股齐升！Xenon制药飙升近50%，癫痫新药临床试验获重大突破；HIMS大涨40%，获诺和诺德授权销售其减肥药；QURE大涨26%，FDA疫苗负责人将离职，有分析称监管政策或转向灵活>>
03-10 16:46
AN2 Therapeutics Plans Phase 2 Trial Of Oral Epetraborole In Polycythemia Vera; Study To Begin Q3 2026 With Potential For Data Readouts As Early As Q4 And Throughout 2027
Substantial clinical evidence provides rationale to initiate Phase 2 study in PVPhase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027AN2 to host webcast on Wednesday,
03-04 05:01
